Carbylan Therapeutics announced in April that it has suspended further clinical development of its Hydros-TA. The company was pursuing a tactical deal that included an acquisition or merger of the firm. The specialty pharmaceutical company indicated earlier that it had engaged Wedbush PacGrow to advice on the decision to be taken in respect of strategic … Continue reading “Carbylan Therapeutics, Inc. (NASDAQ: CBYL) Suspends Hydros-TA Clinical Development”
